Rhode Island S2109 prohibits insurers and pharmacy benefit managers from requiring reviews for opioid addiction treatment prescriptions.
Rhode Island S2109 amends the Benefit Determination and Utilization Review Act to prohibit insurers and pharmacy benefit managers from requiring or conducting reviews for prescription medicines used in the treatment of alcohol or opioid use disorder. This includes medicines containing methadone, buprenorphine, or naltrexone, or those approved by the FDA for managing these disorders or mitigating opioid withdrawal symptoms. The bill also amends Medicaid benefit reviews to use criteria selected by the executive office of health and human services.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.